Envista Holdings Corp. (NVST) News
Filter NVST News Items
NVST News Results
|Loading, please wait...|
NVST News Highlights
- For NVST, its 30 day story count is now at 24.
- Over the past 23 days, the trend for NVST's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- BEAT, PDS and DUO are the most mentioned tickers in articles about NVST.
Latest NVST News From Around the Web
Below are the latest news stories about Envista Holdings Corp that investors may wish to consider to help them evaluate NVST as an investment opportunity.
Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in Jefferies Virtual Dental Summit on Thursday, February 24th from 6:00 – 6:45 AM PST.
The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.
Here is how Indivior PLC (INVVY) and Envista (NVST) have performed compared to their sector so far this year.
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Envista Holdings Corporation's (NVST) CEO Amir Aghdaei on Q4 2021 Results - Earnings Call Transcript
Envista Holdings Corporation (NVST) Q4 2021 Earnings Conference Call February 09, 2022 5:00 PM ET Company Participants Stephen Keller – Vice President of Investor Relations Amir Aghdaei – President and Chief Executive Officer Howard Yu – Chief Financial Officer Conference Call Participants Elizabeth Anderson – Evercore Jeff Johnson – Baird...
Gainers: Dermata Therapeutics DRMA +35%. Innoviva (INVA) +11%. Mainz Biomed (MYNZ) +9%. Regional Health Properties RHE +9%. Envista Holdings (NVST) +8%.Losers: InfuSystem